8-K: Acasti Pharma Surpasses 50% Enrollment in Pivotal Phase 3 Trial, Anticipates NDA Submission in 2025

Acasti Pharma announced it has surpassed the 50% enrollment milestone in its Phase 3 STRIVE-ON safety trial for GTX-104 and anticipates an NDA submission in the first half of 2025.

Summary

• Acasti Pharma has achieved a significant milestone by surpassing 50% enrollment in its Phase 3 STRIVE-ON safety trial for GTX-104, a treatment for aneurysmal subarachnoid hemorrhage (aSAH).
• The company expects to complete patient enrollment in the STRIVE-ON trial between late 2024 and early 2025.
• A New Drug Application (NDA) submission to the FDA for GTX-104 is anticipated in the first half of calendar year 2025.
• Acasti reported a net loss of $2.6 million, or $0.24 loss per share, for the quarter ended June 30, 2024, compared to a net loss of $4.0 million, or $0.54 per share, for the same quarter in 2023.
• Research and development expenses increased to $2.7 million for the quarter ended June 30, 2024, up from $1.1 million in the same quarter of 2023, primarily due to the STRIVE-ON trial.
• General and administrative expenses were $2.3 million for the quarter ended June 30, 2024, an increase from $1.9 million in the same quarter of 2023, mainly due to legal and professional fees related to a proposed change in jurisdiction of incorporation.
• The company's cash and cash equivalents were $19.4 million as of June 30, 2024, down from $23.0 million as of March 31, 2024.
• Acasti believes it has sufficient cash to support operations into the second calendar quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with significant progress in the Phase 3 trial and a clear timeline for NDA submission. However, the company is still operating at a loss and has decreasing cash reserves, which tempers the overall sentiment.

Positives

• The company has made significant progress in its Phase 3 STRIVE-ON trial, surpassing the 50% enrollment milestone.
• The anticipated NDA submission for GTX-104 in the first half of 2025 is on track.
• The company has reduced its net loss compared to the same quarter last year, from $4.0 million to $2.6 million.
• Acasti has a projected cash runway into the second calendar quarter of 2026, providing financial stability for ongoing operations.
• GTX-104 has the potential to address a significant unmet medical need for aSAH patients, with an estimated addressable market of $300 million in the United States.

Negatives

• The company reported a net loss of $2.6 million for the quarter ended June 30, 2024.
• Cash and cash equivalents decreased from $23.0 million on March 31, 2024 to $19.4 million on June 30, 2024.
• Research and development expenses increased significantly to $2.7 million for the quarter ended June 30, 2024, compared to $1.1 million for the same quarter in 2023.
• General and administrative expenses increased to $2.3 million for the quarter ended June 30, 2024, up from $1.9 million in the same quarter of 2023.

Risks

• The success and timing of regulatory submissions for the Phase 3 STRIVE-ON safety trial for GTX-104 are subject to uncertainty.
• Regulatory requirements and the outcome of the proposed NDA application for GTX-104 are not guaranteed.
• Changes to clinical trial designs and regulatory pathways could impact the timeline and success of the trial.
• Legislative, regulatory, political, and economic developments could affect the company's operations and financial results.
• Actual costs associated with Acasti's clinical trials may differ from management's current expectations.

Future Outlook

Acasti anticipates completing patient enrollment in the STRIVE-ON trial in late 2024 to early 2025 and submitting an NDA to the FDA in the first half of calendar 2025. The company believes it has sufficient cash to support operations into the second calendar quarter of 2026.

Management Comments

• Prashant Kohli, CEO of Acasti, stated that the company surpassed the 50% enrollment milestone in the Phase 3 STRIVE-ON safety trial due to the team's focus on patient enrollment.
• Investigators are enthusiastic about the potential of GTX-104 for the treatment of aSAH, according to Prashant Kohli.

Industry Context

Acasti is focused on developing treatments for rare diseases, specifically aSAH, which has a high unmet medical need. The company's focus on an intravenous formulation of nimodipine (GTX-104) addresses the challenges of administering oral nimodipine to critically ill patients. The company is also exploring options for its other drug candidates, GTX-102 and GTX-101, which have been deprioritized in favor of GTX-104.

Comparison to Industry Standards

• Acasti's focus on rare diseases aligns with a growing trend in the biopharmaceutical industry, where companies are increasingly targeting niche markets with high unmet needs.
• The development of an intravenous formulation of nimodipine (GTX-104) is a novel approach to addressing the challenges of administering oral nimodipine in aSAH patients, which is a common issue in the treatment of this condition.
• The company's progress in the Phase 3 STRIVE-ON trial is a positive sign, as many companies face challenges in clinical trial enrollment and execution.
• Acasti's cash runway into the second quarter of 2026 is a positive indicator of financial stability, which is crucial for a company in the clinical development stage.
• Compared to companies like Biohaven, which also focuses on neurological disorders, Acasti is at a different stage of development, with GTX-104 in Phase 3 trials, while Biohaven has several approved products. However, Acasti's focus on a rare disease could provide a unique market opportunity.

Stakeholder Impact

• Shareholders will be impacted by the progress of the STRIVE-ON trial and the potential for FDA approval of GTX-104.
• Employees are likely to be impacted by the company's financial performance and the progress of its clinical programs.
• Patients with aSAH stand to benefit from the potential approval of GTX-104, which could provide a more effective treatment option.
• Creditors will be impacted by the company's financial stability and its ability to meet its obligations.

Next Steps

• Complete patient enrollment in the Phase 3 STRIVE-ON trial.
• Submit a New Drug Application (NDA) to the FDA for GTX-104.
• Continue to monitor and manage cash flow to ensure operations are supported into the second calendar quarter of 2026.
• Explore options for the development, licensing, or sale of GTX-102 and GTX-101.

Key Dates

Keywords

Acasti Pharma, GTX-104, STRIVE-ON trial, aSAH, aneurysmal subarachnoid hemorrhage, NDA submission, Phase 3 trial, nimodipine, biopharma, clinical trial, FDA